Granisetron transdermal - Abeille Pharmaceuticals

Drug Profile

Granisetron transdermal - Abeille Pharmaceuticals

Alternative Names: AB-1001; Granisetron transdermal - Abeille; Inno-P08002; SyB D-0701; SyB-0701

Latest Information Update: 27 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abeille Pharmaceuticals
  • Developer Abeille Pharmaceuticals; INNOPHARMAX; SymBio Pharmaceuticals
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chemotherapy-induced nausea and vomiting
  • Phase II Radiotherapy-induced nausea and vomiting

Most Recent Events

  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 01 Jun 2015 Phase III development is ongoing
  • 28 Jan 2013 SymBio completes a phase III trial in Radiotherapy induced nausea and vomiting in Japan (NCT01700140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top